Evolution of computational techniques against various KRAS mutants in search for therapeutic drugs: a review article
- 01-12-2025
- Original Article
- Authors
- Ayesha Mehmood
- Mohammed Ageeli Hakami
- Hanan A. Ogaly
- Vetriselvan Subramaniyan
- Asaad Khalid
- Abdul Wadood
- Published in
- Cancer Chemotherapy and Pharmacology | Issue 1/2025
Abstract
KRAS was (Kirsten rat sarcoma viral oncogene homolog) revealed as an important target in current therapeutic cancer research because alteration of RAS (rat sarcoma viral oncogene homolog) protein has a critical role in malignant modification, tumor angiogenesis, and metastasis. For cancer treatment, designing competitive inhibitors for this attractive target was difficult. Nevertheless, computational investigations of the protein’s dynamic behavior displayed the existence of temporary pockets that could be used to design allosteric inhibitors. The last decade witnessed intensive efforts to discover KRAS inhibitors. In 2021, the first KRAS G12C covalent inhibitor, AMG 510, received FDA (Food and drug administration) approval as an anticancer medication that paved the path for future treatment strategies against this target. Computer-aided drug designing discovery has long been used in drug development research targeting different KRAS mutants. In this review, the major breakthroughs in computational methods adapted to discover novel compounds for different mutations have been discussed. Undoubtedly, virtual screening and molecular dynamic (MD) simulation and molecular docking are the most considered approach, producing hits that can be employed in subsequent refinements. After comprehensive analysis, Afatinib and Quercetin were computationally identified as hits in different publications. Several authors conducted covalent docking studies with acryl amide warheads groups containing inhibitors. Future studies are needed to demonstrate their true potential. In-depth studies focusing on various allosteric pockets demonstrate that the switch I/II pocket is a suitable site for drug designing. In addition, machine learning and deep learning based approaches provide new insights for developing anti-KRAS drugs. We believe that this review provides extensive information to researchers globally and encourages further development in this particular area of research.
Advertisement
- Title
- Evolution of computational techniques against various KRAS mutants in search for therapeutic drugs: a review article
- Authors
-
Ayesha Mehmood
Mohammed Ageeli Hakami
Hanan A. Ogaly
Vetriselvan Subramaniyan
Asaad Khalid
Abdul Wadood
- Publication date
- 01-12-2025
- Publisher
- Springer Berlin Heidelberg
- Published in
-
Cancer Chemotherapy and Pharmacology / Issue 1/2025
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843 - DOI
- https://doi.org/10.1007/s00280-025-04767-8
This content is only visible if you are logged in and have the appropriate permissions.